Update shared on 18 Nov 2025
Fair value Decreased 11%Analysts have lowered their price target for Protalix BioTherapeutics from $14.00 to $12.50. They cite more conservative expectations regarding revenue growth and profit margins.
What's in the News
- Chiesi Global Rare Diseases and Protalix BioTherapeutics have requested a re-examination from the European Medicines Agency regarding the proposed Elfabrio® 2 mg/kg every 4 weeks dosing regimen. This follows a negative opinion from the CHMP (Key Developments).
- Infusion-related reactions, including hypersensitivity and anaphylaxis, have been observed in clinical trials of Elfabrio®. Recommendations are in place for monitoring and managing adverse events (Key Developments).
- Protalix BioTherapeutics was added to the S&P Global BMI Index (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has decreased from $14.00 to $12.50.
- Discount Rate has risen slightly from 6.78 percent to 7.06 percent.
- Revenue Growth projection has fallen significantly from 44.92 percent to 8.19 percent.
- Net Profit Margin forecast has decreased from 70.06 percent to 35.40 percent.
- Future P/E multiple has increased substantially from 12.51x to 48.69x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.